A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION

A5142/PH III/洛匹那韦/利托那韦 EFAVIR 用于 HIV-1 感染的初始治疗

• 批准号: 7604175
• 负责人: ROY M. GULICK
• 金额: $ 0.03万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604175
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Failure; Funding; Grant; HIV-1; Infection; Institution; Lamivudine; Lopinavir/Ritonavir; Randomized; Research; Research Personnel; Resources; Source; Time; Toxic effect; Treatment Protocols; United States National Institutes of Health; Zidovudine; efavirenz

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to compare the time to virologic failure pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC, and to compare the time to regimen completion pairwise between the three treatment groups: lopinavir/ritonavir plus efavirenz, lopinavir/ritonavir plus d4T extended release (or zidovudine) plus 3TC, and efavirenz plus d4T extended release (or zidovudine) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的主要目的是比较三个治疗组之间的病毒学失败时间：洛匹那韦/利托那韦加依非韦伦、洛匹那韦/利托那韦加 d4T 缓释剂（或齐多夫定）加 3TC、依非韦伦加 d4T 缓释剂（或齐多夫定） ）加 3TC，并成对比较三个治疗组（洛匹那韦/利托那韦）之间完成治疗方案的时间加依非韦伦、洛匹那韦/利托那韦加 d4T 缓释剂（或齐多夫定）加 3TC，以及依非韦伦加 d4T 缓释剂（或齐多夫定）加 3TC。治疗方案完成将被定义为初始随机治疗方案的任何组成部分的病毒学失败或毒性相关的中止。